CA Patent

CA2802132A1 — Tetrahydro-pyrido-pyrimidine derivatives

Assigned to Novartis AG · Expires 2012-01-12 · 14y expired

What this patent protects

The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I): Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes. (see above formula)

USPTO Abstract

The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I): Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes. (see above formula)

Drugs covered by this patent

Patent Metadata

Patent number
CA2802132A1
Jurisdiction
CA
Classification
Expires
2012-01-12
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.